Multiple Myeloma Clinical Trials in Miami, Florida
24 recruitingMiami, Florida
Showing 1–20 of 24 trials
Recruiting
Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Pfizer87 enrolled43 locationsNCT06215118
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Regeneron Pharmaceuticals387 enrolled40 locationsNCT03761108
Recruiting
Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Multiple Myeloma
Pfizer80 enrolled28 locationsNCT06057402
Recruiting
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami1,000 enrolled1 locationNCT05361694
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA200 enrolled32 locationsNCT05862012
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled238 locationsNCT05020236
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 1
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie55 enrolled15 locationsNCT06223516
Recruiting
Phase 2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
University of Miami33 enrolled3 locationsNCT05530421
Recruiting
Phase 2
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Multiple Myeloma
Carl Ola Landgren, MD, PhD50 enrolled1 locationNCT06100237
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 1
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Multiple Myeloma
Pfizer90 enrolled39 locationsNCT05675449
Recruiting
Phase 2
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Multiple Myeloma
Dickran Kazandjian, MD32 enrolled1 locationNCT06910124
Recruiting
Phase 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
University of Miami104 enrolled1 locationNCT06997081
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.50 enrolled16 locationsNCT05722418
Recruiting
Phase 2
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Dickran Kazandjian, MD28 enrolled1 locationNCT06376526